INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 41h ago
HOUSE PTR1h ago
SEC 13F1h ago
ROBINHOOD CHAIN1h ago
HP
Corporate insider

Heerma Peter

CHIEF COMMERCIAL OFFICERCIK 0001789617

EDGAR filingsOpen in network
Disclosed transactions7
Buys / sells0 / 3
Max Insider Score38
Connections with evidence1

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
5
HP
Heerma PeterCHIEF COMMERCIAL OFFICER
TVTXTravere Therapeutics, Inc.
Option exercise
M—
4,250 sh
May 4, 2026May 6, 2026
traded May 4, 2026
+2dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    Travere Therapeutics, Inc.CHIEF COMMERCIAL OFFICER · Dec 29, 2025
5
HP
Heerma PeterCHIEF COMMERCIAL OFFICER
TVTXTravere Therapeutics, Inc.
Grant or award
A
—
8,500 sh
May 4, 2026
May 6, 2026
traded May 4, 2026
+2d
SEC FORM 4

Evidence

5
HP
Heerma PeterCHIEF COMMERCIAL OFFICER
TVTXTravere Therapeutics, Inc.
Option exercise
M—
4,250 sh
May 4, 2026May 6, 2026
traded May 4, 2026
+2dSEC FORM 4

Evidence

35
HP
Heerma PeterCHIEF COMMERCIAL OFFICER
TVTXTravere Therapeutics, Inc.
Open-market sale
SELL$101K
2,174 sh
May 5, 2026May 6, 2026
traded May 5, 2026
+1dSEC FORM 4

Evidence

9
HP
Heerma PeterCHIEF COMMERCIAL OFFICER
TVTXTravere Therapeutics, Inc.
Grant or award
A—
14.0K sh
Apr 13, 2026Apr 15, 2026
traded Apr 13, 2026
+2dSEC FORM 4

Evidence

38
HP
Heerma PeterCHIEF COMMERCIAL OFFICER
TVTXTravere Therapeutics, Inc.
Open-market sale
SELL$303K
7,215 sh
Apr 14, 2026Apr 15, 2026
traded Apr 14, 2026
+1dSEC FORM 4

Evidence

29
HP
Heerma PeterCHIEF COMMERCIAL OFFICER
TVTXTravere Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$199K
4,980 sh
Dec 24, 2025Dec 29, 2025
traded Dec 24, 2025
+5dSEC FORM 4

Evidence